{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:51:05Z","timestamp":1792813865838,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.amjcard.2018.12.039","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T20:52:02Z","timestamp":1546635122000},"page":"1069-1075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"123","author":[{"given":"Monil","family":"Majmundar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tikal","family":"Kansara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyam","family":"Mithawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5315-6426","authenticated-orcid":false,"given":"Rupak","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyank","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-2750","authenticated-orcid":false,"given":"Rajkumar","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2018.12.039_bib0001","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40256-016-0192-1","article-title":"Optimizing the use of cangrelor in the real world","volume":"17","author":"Qamar","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0004","first-page":"9","article-title":"Variation in patient profiles and outcomes in US and non-US subgroups of the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) PHOENIX trial","author":"Vaduganathan","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11883-016-0617-y","article-title":"Role of new antiplatelet drugs on cardiovascular disease: update on cangrelor","volume":"18","author":"Marcano","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0006","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CRD.0000000000000142","article-title":"Cangrelor: a new route for P2Y12 inhibition","volume":"25","author":"Sible","year":"2017","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0007","doi-asserted-by":"crossref","first-page":"16108","DOI":"10.1074\/jbc.M809780200","article-title":"The P2Y12 antagonists, 2-methylthioadenosine 5\u2032-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels","volume":"284","author":"Srinivasan","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0008","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0009","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0010","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0011","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11239-015-1233-3","article-title":"Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials","volume":"40","author":"Angiolillo","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0012","unstructured":"FDA. KENGREAL: Highlights of Prescribing Information (US Food & Drug Administration website). 2015."},{"key":"10.1016\/j.amjcard.2018.12.039_bib0013","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1310\/hpj5010-922","article-title":"Cangrelor","volume":"50","author":"Baker","year":"2015","journal-title":"Hospital Pharmacy"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0014","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcin.2014.09.025","article-title":"Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (a clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention [PCI])","volume":"8","author":"White","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0015","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0016","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0018","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MCA.0000000000000311","article-title":"Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists","volume":"27","author":"Schneider","year":"2016","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0019","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/joic.12229","article-title":"Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation","volume":"28","author":"Schneider","year":"2015","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MCA.0000000000000158","article-title":"Pharmacodynamic effects during the transition between cangrelor and prasugrel","volume":"26","author":"Schneider","year":"2015","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0021","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcin.2013.08.017","article-title":"Pharmacodynamic effects during the transition between cangrelor and ticagrelor","volume":"7","author":"Schneider","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0022","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ejcts\/ezy289","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"55","author":"Sousa-Uva","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0023","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.resuscitation.2006.07.013","article-title":"Acute ST-elevation myocardial infarction after successful cardiopulmonary resuscitation","volume":"72","author":"Gorjup","year":"2007","journal-title":"Resuscitation"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","article-title":"Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap","volume":"170","author":"Alexopoulos","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0025","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.jcin.2016.06.046","article-title":"Efficacy and safety of cangrelor in preventing periprocedural complications in patients with stable angina and acute coronary syndromes undergoing percutaneous coronary intervention: the CHAMPION PHOENIX trial","volume":"9","author":"Abtan","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0026","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2018.12.039_bib0027","first-page":"e362","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919300426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919300426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T20:50:32Z","timestamp":1551991832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919300426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0002914919300426"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.12.039","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2018.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}